期刊
ACS NANO
卷 10, 期 4, 页码 4184-4191出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.5b07408
关键词
multimodal imaging; diagnostic imaging; nuclear signal blocking; tumor targeting; magnetoferritin nanoparticles
类别
资金
- National Natural Science Foundation of China [81571728, 81201698, 31530026, 81471706, 81201130, 81271608]
- National Science and Technology Major Project [2013ZX10004102, 2012ZX10002-009016, 2016ZX10002014-006]
- Shanghai Pujiang Programme [13PJ1401400]
- Shanghai Municipal Commission of Health and Family Planning [XYQ2013106]
- 973 Program [2012CB934003]
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDA09030306]
- Youth Innovation Promotion Association CAS
Despite all the advances in multimodal imaging, it remains a significant challenge to acquire both magnetic resonance and nuclear imaging in a single dose because of the enormous difference in sensitivity. Indeed, nuclear imaging is almost 10(6)-fold more sensitive than magnetic resonance imaging (MRI); thus, repeated injections are generally required to obtain sufficient MR signals after nuclear imaging. Here, we show that strategically engineered magnetoferritin nanoprobes can image tumors with high sensitivity and specificity using SPECT and MRI in living mice after a single intravenous injection. The magnetoferritin nanoprobes composed of I-125 radionuclide-conjugated human H-ferritin iron nanocages (I-125-M-HFn) internalize robustly into cancer cells via a novel tumor-specific HFn-TfR1 pathway. In particular, the endocytic recycling characteristic of TfRl transporters solves the nuclear signal blocking issue caused by the high dose nanoprobes injected for MRI, thus enabling simultaneous functional and morphological tumor imaging without reliance on multi-injections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据